Literature DB >> 21123801

Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.

Rajesh K Sharma, Sankarathi Balaiya, Kakarla V Chalam.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21123801      PMCID： PMC3055783          DOI： 10.1167/iovs.10-6275

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN： 0146-0404            Impact factor:   4.799


× No keyword cloud information.
  9 in total

Review 1.  Lymphangiogenesis and tumor metastasis: myth or reality?

Authors:  M S Pepper
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

2.  Recombinant human VEGF165b inhibits experimental choroidal neovascularization.

Authors:  Jing Hua; Christine Spee; Satoru Kase; Emma S Rennel; Anette L Magnussen; Yan Qiu; Alex Varey; Sandeep Dhayade; Amanda J Churchill; Steven J Harper; David O Bates; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-17       Impact factor: 4.799

3.  Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model.

Authors:  Imren Akkoyun; Gulten Karabay; Nihan Haberal; Attila Dagdeviren; Gursel Yilmaz; Sibel Oto; Leyla Erkanli; Yonca A Akova
Journal:  Acta Ophthalmol       Date:  2010-08-04       Impact factor: 3.761

4.  Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.

Authors:  Inbal Avisar; Dov Weinberger; Israel Kremer
Journal:  Curr Eye Res       Date:  2010-02       Impact factor: 2.424

5.  Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.

Authors:  Sabrina Höbel; Ivette Koburger; Matthias John; Frank Czubayko; Philipp Hadwiger; Hans-Peter Vornlocher; Achim Aigner
Journal:  J Gene Med       Date:  2010-03       Impact factor: 4.565

6.  Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.

Authors:  Chelsey Woodrum; Alison Nobil; Sandra L Dabora
Journal:  J Transl Med       Date:  2010-02-10       Impact factor: 5.531

7.  Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.

Authors:  Lauren M Hook; Jialing Huang; Ming Jiang; Richard Hodinka; Harvey M Friedman
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

8.  Nucleotide sequence and expression of the porcine vascular endothelial growth factor.

Authors:  H S Sharma; Z H Tang; B C Gho; P D Verdouw
Journal:  Biochim Biophys Acta       Date:  1995-01-25

9.  Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.

Authors:  Felix Bock; Jasmine Onderka; Tina Dietrich; Björn Bachmann; Friedrich E Kruse; Matthias Paschke; Grit Zahn; Claus Cursiefen
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799
  9 in total
  5 in total

1.  ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer.

Authors:  Peng Guo; Jiang Yang; Di Jia; Marsha A Moses; Debra T Auguste
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

Review 2.  Clinicopathological and prognostic significance and molecular mechanisms governing uveal melanoma.

Authors:  Meng-Yu Wu; Tzu-Ting Lai; Wan-Ting Liao; Chia-Jung Li
Journal:  Ther Adv Med Oncol       Date:  2020-06-08       Impact factor: 8.168

3.  Bevacizumab Diminishes Inflammation in an Acute Endotoxin-Induced Uveitis Model.

Authors:  Salvador Mérida; María Sancho-Tello; Inmaculada Almansa; Carmen Desco; Cristina Peris; Mari-Luz Moreno; Vincent M Villar; Amparo Navea; Francisco Bosch-Morell
Journal:  Front Pharmacol       Date:  2018-06-19       Impact factor: 5.810

4.  Progression of choroidal metastasis of ovarian serous cystoadenocarcinoma after intravitreal bevacizumab treatment.

Authors:  Irene C Kuo; Ruben H Sambuelli; Javier Bono; Ricardo J Smith; Victor E Reviglio
Journal:  Rare Tumors       Date:  2013-03-04

Review 5.  The roles and mechanisms of hypoxia in liver fibrosis.

Authors:  Jingyao Cai; Min Hu; Zhiyang Chen; Zeng Ling
Journal:  J Transl Med       Date:  2021-05-01       Impact factor: 8.440
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.